FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to new oxyindole derivatives of formula (I) or their pharmaceutically acceptable salts, based pharmaceutical compositions and using them for treating various disorders, which are mediated through the motilin receptor (GPR38). In general formula I, R1 means hydrogen, C1-C4alkyl or C3-C7cycloalkyl； R2 means C1-C4alkyl or C3-C7cycloalkyl； or R1 and R2 together with atoms which they are bound to, form a 3-6-merous ring, which can contain oxygen； R3 and R4 mean hydrogen or C1-C4alkyl； R5 means hydrogen or C1-C4alkyl； R6 and R7 mean hydrogen, C1-C4alkyl or C1-C4alkoxy C1-C4alkyl； or R6 and R7 together with a nitrogen atom which they are bound to, form a 4-6-merous ring, which can contain nitrogen or oxygen； the 4-6-merous ring is optionally substituted by 1-4 substitutes specified in a group consisting of C1-C4alkyl, amino, C1-C4alkylamino and di(C1-C4alkyl)amino； A means or , wherein p, q and r independently have the values of 0, 1 or 2； R8 and R9 mean hydrogen or C1-C6alkyl； wherein alkyl is optionally substituted by hydroxy, C1-C4alkyl, amino, C1-C4alkylamino and di(C1-C4alkyl)amino； or R8 and R9 can be combined to form a C3-C7-merous ring； or R8 and R9 can be independently combined with one or both R8 and R9 groups to form alkylene bridges between terminal nitrogen and an alkyl part of R8 or R9 groups； the bridge contains 1 to 5 carbon atoms； the above bridge is optionally substituted by 1-4 C1-C4 alkyl groups； W means N-R10, the above R10 means hydrogen or C1-C4alkyl； X means C0-C4alkylene or C0-C4alkylene-K-C0-C4alkylene, wherein K means -O- and wherein alkylene is optionally substituted by C1-C4alkyl； Y means hydrogen or a 5-10-merous ring； the above ring is optionally substituted by hydroxyl, halogen, halogen C1-C4alkyl, C1-C4alkyl or C1-C4alkoxy； provided X means C0, Y means other than hydrogen； Z means halogen or C1-C4alkyl； m has the value of 0, 1, 2, 3 or 4； n has the value of 0, 1 or 2.EFF
